Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01705509 · ClinicalTrials.gov registry record · NA
The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)
A NA study, sponsored by Cardiovascular Institute of the South Clinical Research Corporation.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT01705509 is a NA study that was terminated before completion, run by Cardiovascular Institute of the South Clinical Research Corporation. The registered enrollment target is 14 participants.
The verdict
NCT01705509, a NA study, was terminated before completion, sponsored by Cardiovascular Institute of the South Clinical Research Corporation.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a proof of concept trial using ranolazine, a medication, in patients with known Coronary Artery Disease and reduced left ventricular function, EF \< 40%. We propose that ranolazine therapy will result in demonstrative improvements in cardiac function that can be objectively assessed using the parameters measured with CPET. We propose that demonstrative improvement in CPET parameters on ranolazine will translate into improved patient outcomes for this patient population.
Interventions
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-09 |
| Est. Completion | 2017-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01705509
The ClinicalTrials.gov registry entry for NCT01705509 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cardiovascular Institute of the South Clinical Research Corporation, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ranolazine is the first listed.
NCT01705509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01705509 about?
NCT01705509 is a clinical study titled "The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)". This is a proof of concept trial using ranolazine, a medication, in patients with known Coronary Artery Disease and reduced left ventricular function, EF \< 40%. We propose that ranolazine therapy will result in demonstrative improvements in cardiac function that can be objectively assessed using th...
What is the current status of trial NCT01705509?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2012-09. Estimated completion is 2017-03-31.
What interventions are being tested in trial NCT01705509?
The interventions under investigation include: Ranolazine (DRUG).
Who is sponsoring clinical trial NCT01705509?
This trial is sponsored by Cardiovascular Institute of the South Clinical Research Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.